ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,602.07
-0.22%
Dow Jones
41,639.39
-0.65%
US Dollar vs MXN
20.33975
-0.08%
Brent Oil
70.035
1.44%
Bitcoin
81,141.81
3.41%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) Noticias

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CYTO
FechaHoraFuenteTítuloSímboloCompañía
10/03/202515:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
20/12/202407:00GlobeNewswire Inc.Altamira Therapeutics Announces Transition from NASDAQ to OTC MarketsNASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202415:01GlobeNewswire Inc.Altamira Therapeutics Provides Update on Nasdaq ListingNASDAQ:CYTOAltamira Therapeutics Ltd
27/09/202408:01GlobeNewswire Inc.Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayNASDAQ:CYTOAltamira Therapeutics Ltd
24/09/202407:01GlobeNewswire Inc.Altamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
20/09/202408:01GlobeNewswire Inc.Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
19/09/202415:01GlobeNewswire Inc.Altamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
18/09/202415:19Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
17/09/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
17/09/202416:00GlobeNewswire Inc.Altamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingNASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202412:55Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
16/09/202407:30GlobeNewswire Inc.Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaNASDAQ:CYTOAltamira Therapeutics Ltd
03/09/202408:01GlobeNewswire Inc.Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11NASDAQ:CYTOAltamira Therapeutics Ltd
23/08/202408:01GlobeNewswire Inc.Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkNASDAQ:CYTOAltamira Therapeutics Ltd
22/08/202415:53Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
16/08/202408:01GlobeNewswire Inc.Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesNASDAQ:CYTOAltamira Therapeutics Ltd
12/08/202408:02GlobeNewswire Inc.Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsNASDAQ:CYTOAltamira Therapeutics Ltd
19/07/202408:01GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesNASDAQ:CYTOAltamira Therapeutics Ltd
08/07/202416:17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CYTOAltamira Therapeutics Ltd
20/06/202408:01GlobeNewswire Inc.Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementNASDAQ:CYTOAltamira Therapeutics Ltd
28/05/202409:31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202407:47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202407:47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202407:47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202407:00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202407:45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202407:47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
07/02/202407:47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
24/01/202407:47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202415:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO

Su Consulta Reciente

NYSE
CVX
Chevron
NYSE
MRK
Merck
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BASFY
BASF (QX)
FX
EURUSD
Euro vs US Dollar
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
AMEX
SPY
SPDR S&P 500
NASDAQ
AAPL
Apple
COIN
AVAXUSD
Avalanche
COIN
DOGEUSD
Dogecoin
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios